Loading...
•
Jun 30, 2022
Ultragenyx Q2 2022 Earnings Report
Second quarter financial results reported with total revenue of $89.3 million and Crysvita revenue of $64.0 million.
Key Takeaways
Ultragenyx reported second quarter revenue of $89.3 million, including $64.0 million from Crysvita and $13.5 million from Dojolvi. They completed the sale of a capped 30% royalty interest on future Crysvita sales for $500 million and acquired GeneTx. The company reaffirmed its 2022 revenue guidance for Crysvita and Dojolvi.
Total revenue for the second quarter of 2022 was $89.3 million.
Crysvita revenue in Ultragenyx territories was $64.0 million.
Dojolvi product sales were $13.5 million.
Net loss for the quarter was $158.2 million, or $2.26 per share.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
The company continues to expect 2022 revenue for Crysvita in Ultragenyx territories to be between $250 million and $260 million and Dojolvi revenue to be between $55 million and $65 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...